Uttar Pradesh News Desk

NR2E3 Mutation-Associated Retinal Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

NR2E3 Mutation-Associated Retinal Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

January 12
22:20 2023
NR2E3 Mutation-Associated Retinal Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “NR2E3 mutation-associated retinal degeneration Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the NR2E3 mutation-associated retinal degeneration, historical and forecasted epidemiology as well as the NR2E3 mutation-associated retinal degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “NR2E3 mutation-associated retinal degeneration Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the NR2E3 mutation-associated retinal degeneration, historical and forecasted epidemiology as well as the NR2E3 mutation-associated retinal degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The NR2E3 mutation-associated retinal degeneration market report provides current treatment practices, emerging drugs, NR2E3 mutation-associated retinal degeneration market share of the individual therapies, current and forecasted NR2E3 mutation-associated retinal degeneration market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current NR2E3 mutation-associated retinal degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the NR2E3 mutation-associated retinal degeneration market

Some of the key facts of  NR2E3 Mutation-Associated Retinal Degeneration Market Report:

  • In a study by Passali et al (2018), the prevalence of Allergic Rhinitis (AR) was reported to be 15%–25%. The most common aeroallergens were pollen and mites (67.31%). The tested pollens by the participants in the prick test included grass mix (32.69%), Artemisia vulgaris, Parietaria officinalis and Ambrosia eliator (15.38%), Betula verrucose or Betulaceae mix and Platanus occidentalis (13.46%), Cupressaceae (11.54%), and Oleaceae (9.62%).

  • According to Tanaka et al. (2012), the prevalence of AR and Japanese cedar pollinosis was 23.4% and 26.5%, respectively, in Japan. The prevalence rate of Japanese cedar pollinosis in children was reported to be in the range of 13.8% – 22.9%. The survey was executed in 407 to 510 children in May or June every year from 1995 to 2001. The prevalence rate of pollinosis was found to be related to the amount of pollen in the air. 

Key Benefits of the Report:

  • The report covers a descriptive overview of NR2E3 mutation-associated retinal degeneration, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

  • Comprehensive insight has been provided into the NR2E3 mutation-associated retinal degeneration epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for NR2E3 mutation-associated retinal degeneration is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of NR2E3 mutation-associated retinal degeneration market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global NR2E3 mutation-associated retinal degeneration  market

 

Got queries? Click here to know more about the  NR2E3 Mutation-Associated Retinal Degeneration Market Landscape 

 

NR2E3 Mutation-Associated Retinal Degeneration Overview

 

NR2E3 mutation-associated retinal degeneration, also called “hay fever” or “pollinosis”, is an allergic condition affecting the mucous membranes of the nose and the eyes. It is usually characterized by nasal discharge, nasal congestion, itchy, watery eyes, itchy nose, inner ears, and roof of the mouth. These symptoms are caused by a hypersensitivity to airborne pollen such as the pollen of trees, grasses, and weeds. The allergen comes in contact with cell-bound immunoglobulin E (IgE) in the tissues of the body’s conjunctiva and nasal mucosa, the tissues release mediators such as histamine or leukotrienes and induce annoying allergic symptoms. vAs with other allergies, the best treatment is to avoid the allergen. However, pollen is very difficult to avoid. If patients still experience symptoms despite taking these preventive measures, there are several over-the-counter (OTC) medications like antihistamines, such as cetirizine (Zyrtec) or diphenhydramine (Benadryl); decongestants, such as pseudoephedrine (Sudafed) or oxymetazoline (Afrin nasal spray); and medications that combine an antihistamine and a decongestant, such as Actifed (triprolidine and pseudoephedrine) and Claritin-D (loratadine and pseudoephedrine). Allergy shots are a form of immunotherapy that involves a series of injections of the allergen. The amount of allergen in the shot gradually increases over time. The shots modify the immune system’s response to the allergen, helping to reduce the severity of your allergic reactions. The patients experience complete relief within one to three years after starting allergy shots. The pollen allergies market is expected to witness market growth in the forecast period. The rise in the number of patients especially children suffering from pollen allergies would escalate the growth of the pollen allergies market.

 

 

NR2E3 Mutation-Associated Retinal Degeneration Epidemiology Insights: 

 

  • According to the World Allergy Organization (2016), in the International Study of Asthma and Allergies in Childhood (ISAAC), self-reported NR2E3 mutation-associated retinal degeneration  (hay fever) prevalence in 13- to 14-yr-old children was 22.1% as a global total. It differs among regions: 23.7% in Latin America, 33.3% in North America, 12.3% in Northern & Eastern Europe, and 21.2% in Western Europe.  

  • According to Centers for Disease Control and Prevention (2018), 19.2 million (7.6%) adults (18 and above) were diagnosed with hay fever, it was more prevalent in women (8.3%) than men (6.4%), while 5.2 million children (7.2%) were reported hay fever, it was more prevalent in boys (7.9%) than girls (6.4%).

 

NR2E3 mutation-associated retinal degeneration Epidemiological Segmentation 

  • NR2E3 mutation-associated retinal degeneration prevalent cases 

  •  NR2E3 mutation-associated retinal degeneration gender-specific cases 

  • NR2E3 mutation-associated retinal degeneration age-specific cases 

  • NR2E3 mutation-associated retinal degeneration type-specific cases 

 

NR2E3 mutation-associated retinal degeneration Market Outlook 

The NR2E3 mutation-associated retinal degeneration market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted NR2E3 mutation-associated retinal degeneration market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

 

This segment gives a thorough detail of the NR2E3 mutation-associated retinal degeneration  market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

According to DelveInsight, the NR2E3 mutation-associated retinal degeneration market in 7MM is expected to change in the study period 2019-2032.

 

Learn more by requesting for sample @ NR2E3 mutation-associated retinal degeneration Market Landscape

 

Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of  NR2E3 mutation-associated retinal degeneration    Market 

  4. Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  NR2E3 mutation-associated retinal degeneration Market Emerging Therapies

  9.  NR2E3 mutation-associated retinal degeneration Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Appendix

  12.  NR2E3 mutation-associated retinal degeneration Market Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

  15.  About DelveInsight

Click here to read more about NR2E3 Mutation-Associated Retinal Degeneration Market Landscape

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/

Related Articles